Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells.
about
BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.Exploring the yeast acetylome using functional genomicsQuantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, VorinostatProtein analysis by shotgun/bottom-up proteomicsSuberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future OpportunitiesMonoclonal antibody cocktail as an enrichment tool for acetylome analysisExpression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma.Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells.Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.Secretome Analysis of Skeletal Myogenesis Using SILAC and Shotgun Proteomics.Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.Inhibition of histone deacetylases.Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines.Replication-dependent histone isoforms: a new source of complexity in chromatin structure and function
P2860
Q33643334-1AD1EA6B-79AB-4EB8-8C3D-20C82DABB840Q34111422-FFF0FED6-229F-4CD9-B70C-5A0C73684212Q34145178-3852C2A3-A305-4543-8771-900B7C65A808Q34213967-07BE3918-5CFD-4916-8F85-8DBAC9DB89B6Q34600986-D415EB92-3DF5-44C0-9A0C-B4F5BFBFE98DQ34810920-42A5AE52-E2BC-4D13-BA64-776D49B76A8FQ35185640-35C0CD20-89C2-42E8-8B02-D09304CEE1C8Q35492528-5B3F444C-5F4B-44B4-930F-05028366327EQ35953149-0967138C-3B37-4A34-A0CE-1CB8341CDC13Q36142170-7D986A77-29C4-4439-836B-4BCD976F7934Q37031561-EFBCB411-75BB-4116-9092-5CF368875567Q38805063-1546AB1D-8A94-488F-B6A1-A974A5F1DCF9Q38989476-1B923B60-C6AD-4122-BB12-7542FBCF8F9BQ39771650-3ABC2D49-1F04-4F38-B47E-55DF85F1FDD4Q41612823-FB791DAE-021C-4DEF-9D1F-5F9EC765F5B3Q41650051-19433080-EC08-4360-BB40-9D9A0A0BA97FQ54941547-FDA507BD-BBE3-4E20-AC7D-2F3D84CDEB20Q58700196-D1FAE254-F22B-4330-9607-B3D895CB1A35
P2860
Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Screening for therapeutic targ ...... in human breast cancer cells.
@ast
Screening for therapeutic targ ...... in human breast cancer cells.
@en
type
label
Screening for therapeutic targ ...... in human breast cancer cells.
@ast
Screening for therapeutic targ ...... in human breast cancer cells.
@en
prefLabel
Screening for therapeutic targ ...... in human breast cancer cells.
@ast
Screening for therapeutic targ ...... in human breast cancer cells.
@en
P2093
P2860
P356
P1433
P1476
Screening for therapeutic targ ...... in human breast cancer cells.
@en
P2093
Akhilesh Pandey
Nancy E Davidson
Patrick G Shaw
Raghothama Chaerkady
Thomas W Kensler
P2860
P304
P356
10.1002/PMIC.200900602
P577
2010-03-01T00:00:00Z